Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomise...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Blanco, Ricardo, Maldonado Cocco, Jose, Chen, Ying-Chou, Gaich, Carol L, DeLozier, Amy M, de Bono, Stephanie, Liu, Jiajun, Rooney, Terence, Chang, Cecile Hsiao-Chun, Dougados, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372156/
https://www.ncbi.nlm.nih.gov/pubmed/28405473
http://dx.doi.org/10.1136/rmdopen-2016-000410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372156/
https://www.ncbi.nlm.nih.gov/pubmed/28405473
http://dx.doi.org/10.1136/rmdopen-2016-000410

Ejemplares similares